GenSight Biologics
SIGHT.PA$20M
Micro CapEuronext ParisBiotechnology🇫🇷Europe13 employees
Drugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
SIGHT.PA News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GS010 | Phase 3 | Optic, Atrophy, Hereditary, Leber | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply